Fulton Breakefield Broenniman LLC Decreases Stock Holdings in Danaher Corporation $DHR

Fulton Breakefield Broenniman LLC lowered its stake in shares of Danaher Corporation (NYSE:DHR) by 1.7% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 71,675 shares of the conglomerate’s stock after selling 1,225 shares during the period. Fulton Breakefield Broenniman LLC’s holdings in Danaher were worth $14,159,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently modified their holdings of DHR. Nuveen LLC purchased a new stake in shares of Danaher in the first quarter valued at about $833,941,000. Invesco Ltd. lifted its holdings in shares of Danaher by 44.5% in the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after purchasing an additional 1,450,703 shares in the last quarter. Baird Financial Group Inc. lifted its holdings in shares of Danaher by 290.6% in the first quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate’s stock valued at $295,550,000 after purchasing an additional 1,072,617 shares in the last quarter. Generation Investment Management LLP lifted its holdings in shares of Danaher by 33.2% in the first quarter. Generation Investment Management LLP now owns 3,178,124 shares of the conglomerate’s stock valued at $651,515,000 after purchasing an additional 791,662 shares in the last quarter. Finally, Parnassus Investments LLC lifted its holdings in shares of Danaher by 23.3% in the first quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate’s stock valued at $784,745,000 after purchasing an additional 722,636 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of DHR stock opened at $205.13 on Thursday. Danaher Corporation has a one year low of $171.00 and a one year high of $279.41. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. The company has a 50 day moving average price of $200.41 and a 200 day moving average price of $197.38. The firm has a market capitalization of $146.88 billion, a price-to-earnings ratio of 43.64, a price-to-earnings-growth ratio of 2.97 and a beta of 0.77.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. During the same period in the previous year, the firm earned $1.72 earnings per share. Danaher’s revenue for the quarter was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Sell-side analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, September 26th. Danaher’s payout ratio is currently 27.23%.

Insider Transactions at Danaher

In other Danaher news, Director Teri List sold 2,778 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares in the company, valued at $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 11.10% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on DHR shares. Wells Fargo & Company cut their price objective on shares of Danaher from $210.00 to $205.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 23rd. Scotiabank raised shares of Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 price objective for the company in a research report on Friday, July 11th. Weiss Ratings reissued a “hold (c-)” rating on shares of Danaher in a research report on Wednesday. UBS Group cut their price objective on shares of Danaher from $240.00 to $225.00 and set a “buy” rating for the company in a research report on Wednesday, July 23rd. Finally, Barclays reissued an “overweight” rating and issued a $225.00 price objective (up previously from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Seventeen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and a consensus price target of $244.60.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.